Vertex Pharma (VRTX) Tops Q4 EPS by 13c, offers guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
Revenue Growth %: +10.7%
Financial Fact:
Collaborative revenues: 259K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +10.7%
Financial Fact:
Collaborative revenues: 259K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
(Updated - February 5, 2024 4:49 PM EST)
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $4.20, $0.13 better than the analyst estimate of $4.07. Revenue for the quarter came in at $2.52 billion versus the consensus estimate of $2.51 billion.
GUIDANCE:
Vertex Pharma sees Q1 2024 revenue of $10.55-10.75 billion, versus the consensus of $10.61 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
